Early Mortality Following CAR-T Therapy in Hematologic Malignancies: A Population-Level Study

Breyanzi (lisocabtagene maraleucel) - BMS

Kymriah (tisagenlecleucel-T) - Novartis

Carvykti (ciltacabtagene autoleucel) - J&J

Yescarta (axicabtagene ciloleucel) - Gilead

Abecma (idecabtagene vicleucel) - BMS

https://www.sciencedirect.com/science/article/abs/pii/S2152265026032039

Nanditha Karra MD 1; Harshal Chorya MBBS 2; Sai Lahari Sangaraju MD 3; Gowrishankar Palaniswamy MD 4; Sai Mourya Meda MBBS 5; Thanuja Mora DNB 6; Sweta Sahu MBBS 7

Sep 1, 2026